MORRISVILLE, N.C., Jan. 11, 2016 /PRNewswire/ -- TearScience, a privately held medical device company, has announced 35% sales growth year over year. The number of practices purchasing the company's diagnostic and treatment for meibomian gland disease (MGD) and dry eye doubled in 2015 while the number of patients treated increased 60%. Since Joseph Boorady's appointment as Chief Executive Officer, TearScience has executed a strategy of practice and patient accessibility. In 2015 the company launched Dynamic Meibomian Imaging (DMI) to improve understanding of the disease and responded to input from eye care professionals and patients by making revisions to the cost of capital and disposable activators for patient treatments.
"LipiFlow and LipiView are breakthrough technologies for a previously unmet need. Adding Dynamic Meibomian Imaging and aligning key elements of the business model to the market have led to the results we were able to post in 2015. Those changes have set the stage for even greater results in 2016 and beyond," said Dr. Boorady, President and CEO of TearScience.
In November, TearScience experienced the most successful American Academy of Ophthalmology (AAO) in company history. Significant sales at AAO were attributed to greater overall recognition of MGD as a primary cause of dry eye and to the announcement in late October of a 50% reduction in the price of disposable activators used during treatments.
Recognition of the potential for MGD to disrupt vision and impact ocular health has grown among Eye Care Professionals (ECPs) since results of the MGD workshop were published in 2011. MGD is chronic and progressive. It is believed poor blinking habits due in part to an increased use of display technology in modern lifestyles contributes to its high prevalence. The LipiFlow treatment safely and comfortably clears blockages in Meibomian glands. In a recent review of 31 sponsored and unsponsored peer-reviewed reports, a single LipiFlow treatment was shown to improve mean meibomian gland secretions, critical to stability of the tear film, while reducing patient reported symptom scores over sustained periods.
According to Richard L. Lindstrom, MD, founder and attending surgeon of Minnesota Eye Consultants, "Soon after taking the helm at TearScience, Joe Boorady sought advice of Eye Care Professionals in achieving greater acceptance of these well studied and effective technologies. It is gratifying to see the resulting decisions yield such positive results for patients and practices."
TearScience, a medical device company, has pioneered technologies and continues to lead innovation that vastly improves evaluation and treatment of meibomian gland disease (MGD). A progressive, obstructive disease and a root cause of dry eye, MGD is distinguished by loss of function and structure of tear oil glands. MGD affects approximately 86% of the 300 million dry eye sufferers worldwide and is highly prevalent in the general ophthalmic population. LipiView II with Dynamic Meibomian Imaging (DMI) distinctively images meibomian gland structure. The Korb Meibomian Gland Evaluator™ assists physicians to reproducibly assess gland function. LipiFlow uses Vectored Thermal Pulse™ (VTP) technology to precisely direct inner-lid treatment that following clinical study was granted clearance by the US Food and Drug Administration for use in patients with MGD. Sponsored and unsponsored multicenter, randomized, controlled clinical studies of LipiFlow support its safety and sustained effectiveness. For additional information on how TearScience improves evaluation of MGD, meibomian gland function, and symptoms for patients with MGD worldwide, visit www.TearScience.com.
Pascale Communications, LLC